For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Group 3 | BOOI\<20, BCI≥ 100) alfuzosin : 10mg, once daily, 12months | None | None | 0 | 41 | 2 | 41 | View |
| Group 4 | BOOI\<20, BCI\<100 alfuzosin : 10mg, once daily, 12 months | None | None | 0 | 54 | 2 | 54 | View |
| group1 | BOOI≥ 20, BCI≥ 100 alfuzosin : 10mg, once daily, 12months | None | None | 0 | 61 | 2 | 61 | View |
| group2 | BOOI≥ 20, BCI\<100 alfuzosin : 10mg, once daily, 12months | None | None | 0 | 76 | 3 | 76 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| dizziness | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |